Actively Recruiting
Prospective Multicenter Study on Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Receiving Alectinib Adjuvant Therapy in China
Led by Hoffmann-La Roche · Updated on 2026-10-06
800
Participants Needed
44
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the real-world clinical outcomes of adult patients in China who have had surgery for stage II to IIIB anaplastic lymphoma kinase ALK-positive non-small-cell lung cancer NSCLC and were treated with Alectinib as adjuvant therapy. This multicenter, prospective cohort study aims to better understand the disease-free survival and other clinical characteristics of these patients over time. Participants in this observational study have already received Alectinib following their surgery as part of routine clinical care. The study does not provide any additional treatments but follows patients who have taken Alectinib monotherapy without prior systemic therapy, including other ALK-targeted therapies or chemotherapy. Patients will be observed during their routine clinical visits for about 2.5 years. During the study, researchers will collect information on disease recurrence or death, treatment duration, participant demographics, clinical characteristics including performance status and surgery history, and quality of life using questionnaires every three months. Adverse events related to Alectinib will also be monitored from baseline until 28 days after the last dose or withdrawal. The total follow-up period for each participant is approximately 2.5 years.
CONDITIONS
Brief Title
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Research Team
R
Reference Study ID Number: ML45766 https://forpatients.roche.com/ No attachments to email below.
F
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here